Compare SCHL & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCHL | BIOA |
|---|---|---|
| Founded | 1920 | 2015 |
| Country | United States | United States |
| Employees | N/A | 62 |
| Industry | Books | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 842.4M | 681.9M |
| IPO Year | 1995 | N/A |
| Metric | SCHL | BIOA |
|---|---|---|
| Price | $43.61 | $17.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $40.00 | ★ $51.50 |
| AVG Volume (30 Days) | 240.7K | ★ 369.2K |
| Earning Date | 03-19-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.87 | N/A |
| Revenue | ★ $1,487,100,000.00 | N/A |
| Revenue This Year | $1.88 | $720.93 |
| Revenue Next Year | $4.05 | N/A |
| P/E Ratio | $23.26 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $18.26 | $4.07 |
| 52 Week High | $43.79 | $24.00 |
| Indicator | SCHL | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 66.20 | 49.70 |
| Support Level | $37.84 | $15.49 |
| Resistance Level | N/A | $19.01 |
| Average True Range (ATR) | 1.32 | 1.13 |
| MACD | 0.28 | 0.00 |
| Stochastic Oscillator | 98.23 | 65.68 |
Scholastic Corp is an American publishing and education media company that focuses on books and educational material for schools, teachers, parents, and children. It creates print, digital, and audiobooks, learning materials and programs, classroom magazines, and other products that support children's learning and reading both at home and at school. The company also owns rights to various books, including Harry Potter, Dog Man, and The Hunger Games among others. It has three reportable segments Children's Book Publishing and Distribution, Education Solutions, and International. The majority of its revenue is from the Children's Book Publishing and Distribution segment.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.